The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Janssen
Consulting or Advisory Role - Janssen; Sanofi; Zeneca
Travel, Accommodations, Expenses - Kyowa Kirin; Sanofi
IT-IO: Intrathecal administration of nivolumab and ipilimumab in combination with systemic combination of nivolumab and ipilimumab in patients with non-small cell lung cancer or melanoma and newly diagnosed leptomeningeal metastasis, a multicentric phase I study.
 
Emilie Le Rhun
Honoraria - Bayer (I); Novocure (I); Pierre Fabre
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Biodexa Pharmaceuticals; CureVac (I); Janssen; Leo Pharma; Medac; Medac (I); Novartis; Novartis (I); Orbus Therapeutics (I); Pfizer; Philogen (I); Roche; Roche (I); Sandoz (I); Seagen; SERVIER; SERVIER (I)
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Quercegen Pharmaceuticals (Inst); Versameb (Inst)
 
Dorothee Gramatzki
No Relationships to Disclose
 
Lukas Kraehenbuehl
No Relationships to Disclose
 
Joanna Mangana
Honoraria - BMS; MSD
Consulting or Advisory Role - BMS; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Novartis; Pierre Fabre
Research Funding - BMS (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - L oreal; Pierre Fabre; Sun Pharma
 
Egle Ramelyte
Honoraria - BMS GmbH & Co. KG; Galderma; Lilly; MSD; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; Kyowa Kirin International; Sanofi/Regeneron
Speakers' Bureau - BMS GmbH & Co. KG; MSD; Sanofi/Regeneron
Research Funding - Amgen (Inst); Sanofi/Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Contribution to UpToDate chapter update for Superficial acitic porokeratosis.
Travel, Accommodations, Expenses - Amgen; Pierre Fabre; Sanofi
 
Christian Britschgi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck KGaA; PharmaMar; Roche; Sanofi; Takeda
Research Funding - Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Amgen; MSD Oncology
 
Ulrich Richter
Honoraria - Johnson & Johnson/Janssen; MSD
Consulting or Advisory Role - AstraZeneca; Johnson & Johnson/Janssen; PharmaMar; Takeda
Travel, Accommodations, Expenses - Amgen; AstraZeneca; PharmaMar; Roche
 
Andreas Wicki
Research Funding - Roche (Inst)
 
Susanne Weindler
Research Funding - BMS GmbH & Co. KG (Inst); MSD (Inst)
 
Denis Migliorini
No Relationships to Disclose
 
Heinz Laubli
Leadership - Glycocalyx Therapeutics
Stock and Other Ownership Interests - Glycocalyx Therapeutics; Omnilinx Therapeutics
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
Research Funding - Anaveon; AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlycoEra; Palleon Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent for Siglec-9 Antibody
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck/Schering Plough; Roche
 
Urania Dafni
No Relationships to Disclose
 
Markus Vaas
No Relationships to Disclose
 
Tobias Weiss
Consulting or Advisory Role - Philogen
Research Funding - Cellis (Inst)
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Oncobit; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Simcere; Sun Pharma; T3 Pharmaceuticals; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Oncobit; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Simcere; Sun Pharma; T3 Pharmaceuticals; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Michael Weller
Honoraria - Bayer; Novocure
Consulting or Advisory Role - AstraZeneca (I); Bayer (I); Biodexa (I); Curevac; Janssen (I); LEO Pharma (I); Medac; Medac (I); Novartis; Novartis; Novartis (I); Orbus Therapeutics; Pfizer (I); Philogen; Roche (I); Sandoz; Seagen (I); Seagen (I); Servier; Servier (I)
Research Funding - BMS (Inst); Novartis (Inst); Quercegen Pharmaceuticals (Inst); Versameb (Inst)